Suwanee, GA., (Uptick Newswire – October 3, 2017) – Kevin Richardson, CEO of SANUWAVE Health, Inc. (OTCQB:SNWV) interviews on the Uptick Network Stock Day Podcast with host Everett Jolly. With 65 patents and pending patents, Mr. Richardson reviews one of SANUWAVE’s products dermaPACE technology and what it is doing for the wound care industry. Mr. Richardson discusses a few of the seven goals put into play in the beginning of 2017 to move the company forward for a strong start into 2018. He continues the interview with discussing the diabetic ulcer financial market that is growing substantially and what this growing market could do financially for SANUWAVE. Furthermore, Mr. Richardson reviews additional products that are overseas, products that are in the study process and that are pending for approval.
In closing, Mr. Richardson states, “We’ve been executing, we deliver on what we say, we have established goals that we can achieve that will create long term shareholder value. We set the bar high, we execute and deliver. Last time we were on with you we announced international, we said stay tuned and we delivered that. More evidence of this is today we are announcing the Brazilian joint venture and we are following through on what we promise.” Mr. Richardson continues his closing statement by saying, “I expect for us to have an FDA approval by the end of this year or starting next year. I expect to have another joint venture or exclusivity sometime within the next quarter or two. If we are doing that, we are creating tremendous shareholder value.”
To listen to the full interview please click here or the following link: https://upticknewswire.com/featured-interview-ceo-kevin-richardson-sanuwave-health-inc-otcqb-snwv-2
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB: SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s de novo petition review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
SANUWAVE Health, Inc.
Vice President International Sales and Relations